Whole-body low-temperature radioluminography of 3 H-2,6-xylidine in rats indicates that the nonmetabolized substance, which is a volatile and fat-soluble compound, is distributed throughout the body and accumulates in adipose tissues, e.g., in the abdominal and subcutaneous regions. Whole-body autoradiography with freeze-dried or solvent-extracted tissue sections as well as microautoradiography, which were used to trace tissues in the rats accumulating 2,6-xylidine metabolites, showed presence of tissue-bound 2,6-xylidine metabolites in the nasal olfactory mucosa and the mucosa of the upper alimentary and respiratory tracts. These tissues were found to have an in vitro capacity to bioactivate 2,6-xylidine. Our data indicate that 2,6-xylidine in vivo undergoes an in situ bioactivation in these extrahepatic tissues. Our results showed that the nasal olfactory mucosa had a much higher capacity than the other examined tissues to bioactivate 2,6-xylidine. Thus, the carcinogenic effect of 2,6-xylidine toward the nasal mucosa in rats is correlated with a high capacity of this tissue to bioactivate the compound.
INTRODUCTION
The aromatic amine 2,6-xylidine (2,6-dimethylaniline) is used as a chemical intermediate in the production of dyes, pesticides, and pharmaceuticals (IARC, 1993) . It has also been detected in tobacco and tobacco smoke (Irvine and Saxby, 1969; Patrinakos and Hoffman, 1979) .
Several local anesthetics, such as lidocaine (xylocaine), etidocaine, mepivacaine, ropivacaine, and bupivacaine are made with 2,6-xylidine. The substance has been identified as a metabolite in the urine of rats, guinea-pigs, dogs, and humans given lidocaine orally (Keenaghan and Boyes, 1972) . 2,6-Xylidine has also been shown in samples of milk from bovines given lidocaine during surgery and in breast milk samples of a human donor who received lidocaine during dental work (Puente and Josephy, 2001 ). In addition, the substance has been identified as a major lidocaine metabolite in human liver slices in vitro (Parker et al., 1996) . 2,6-Xylidine has also been shown to be a metabolite excreted in the urine of humans exposed to etidocaine (Thomas et al., 1976) .
The alpha-2-adrenergic agonist xylazine, which is used in veterinary medicine as a sedative, analgesic, and muscle relaxant, consists of 2,6-xylidine coupled to a thiazine ring. In cows given a therapeutic im dose of xylazine a metabolite identified as 2,6-xylidine has been detected in urine up to 10 h after administration (Pütter and Sagner, 1973) . 2,6-Xylidine is an in vivo and in vitro metabolite in rats and humans of the experimental anticonvulsant agent N-(2,6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide (Martin et al., 1997) . The substance is also the major degradation product of the hydrolytic reaction of lidamidine, which is an antidiarrheal agent (Zalipsky et al., 1978) . In addition, 2,6-xylidine has been identified as an impurity of the fungicide metalaxyl (Dureja et al., 2000) .
2,6-Xylidine is a rat nasal carcinogen. Thus, a high incidence of nasal tumors has been observed in rats fed a diet containing 3000 ppm of 2,6-xylidine for 2 years (Kornreich and Montgomery, 1990) . There was also an increased incidence of subcutaneous tissue fibromas in the 2,6-xylidine-treated rats. In rats fed a diet containing 3000 ppm of 2,6-xylidine for 4 weeks atrophy of Bowman's glands was observed in the dorsal meatus of the olfactory region of the nasal cavity (Yasuhara et al., 2000) .
Aromatic amine carcinogens are known to exert their biological effects following cytochrome P-450 (CYP)-mediated metabolic activation to reactive electrophilic intermediates that bind to DNA (Marques et al., 1997) . In the case of 2,6-xylidine, the nitrogen of the amino group and the para position on the aromatic ring are the two possible sites for the initial CYP-mediated monooxygenation, leading to the production of N-(2,6-dimethylphenyl)hydroxylamine (DMHA) and 4-amino-3,5-dimethylphenol (DMAP), respectively ( Fig. 1) . DMHA has the potential to react with DNA either directly or after esterification (Gan et al., 2001; Marques et al., 2002) . DMAP is potentially genotoxic by a mechanism involving nonenzymatic oxidation to an iminoquinone, which is a strong electrophile (Gan et al., 2001) . Indirect evidence for the formation of N-hydroxylated aromatic amines in vivo can be obtained from the detection of hemoglobin adducts, which are formed by covalent binding of the bioactivated amines with cystein residues of the b-chain of hemoglobin (Ringe et al., 1988) .
In rats and dogs DMAP is the major 2,6-xylidine metabolite found in urine (Short et al., 1989a) . Studies using recombinant human CYPs and human liver microsomes have shown that DMAP is the only metabolic product at micromolar concentrations of 2,6-xylidine, whereas at nanomolar 2,6-xylidine concentrations DMHA was a substantial product (Gan et al., 2001 ). CYP2A6 and CYP2E1 were identified as the major CYPs responsible for the formation of DMAP, whereas CYP2A6 was identified as the CYP responsible for the formation of DMHA (Gan et al., 2001) . DMHA can be rearranged to DMAP, and CYP2E1 was shown to catalyze this reaction (Gan et al., 2001 ).
2,6-Xylidine-hemoglobin adduct levels have been found to be elevated in human patients receiving lidocaine treatment for local anesthesia or cardiac arrhythmias, which is indicative that DMHA is a metabolite of lidocaine in man (Bryant et al., 1994) . 2,6-Xylidine-hemoglobin adducts were also found in humans with no known exposure to lidocaine. This was attributed to chronic exposure to iatrogenic or environmental sources of 2,6-xylidine and to the 120-day life span of the erythrocyte (IARC 1993; Bryant et al., 1994) . 2,6-Xylidinehemoglobin adducts have in addition been found in rats given 2,6-xylidine or lidocaine (Bryant et al., 1994) .
Covalent binding of 14 C-2,6-xylidine to DNA has been shown in ethmoid turbinates of rats given the substance orally (Short et al., 1989b) . In addition, a 32 P-postlabeling assay has shown DNA adducts in the nasal mucosa of rats given 2,6-xylidine orally (Jeffrey et al., 2002) .
In the present study we have used whole-body autoradiography with freeze-dried or solvent-extracted tissue sections to trace tissues accumulating extractable and nonextractable metabolites after iv or oral administration of 3 H-labeled 2,6-xylidine in rats. Low-temperature whole-body radioluminography was used to examine the tissue deposition of the volatile 2,6-xylidine. Based on the whole-body autoradiography the detailed localization of tissue-bound 2,6-xylidine metabolites was examined by microautoradiography. In addition, the ability of subcellular fractions of some tissues to form 2,6-xylidine metabolites, which bind to protein and DNA, were studied in vitro.
MATERIALS AND METHODS

Chemicals.
3 H-2,6-xylidine (generally labeled) with a specific radioactivity of 10 Ci/mmol was purchased from Moravek Biochemicals (Brea, CA). Calf thymus DNA, glucose-6-phosphate dehydrogenase, glucose-6-phosphate, nicotinamide adenine dinucleotide (NADP), and metyrapone were purchased from Sigma-Aldrich Co. (St Louis, MO). Other chemicals used in the study were obtained from regular commercial sources.
Animals. Female non-pregnant Sprague-Dawley rats, body weight about 125 g, were obtained from Bantin and Kingman (Sollentuna, Sweden). The animals were housed at 22 C with a 12 h light/dark cycle with free access to tap water and a standard pellet diet (Lactamin AB, Vadstena, Sweden). The Local Ethics Committee for Animal Research approved the study.
Whole-body autoradiography and whole-body radioluminography. Rats were given 3 H-2,6-xylidine (2 mCi [24 mg] /kg body weight, given in 60% ethanol [1.2 ml/kg body weight]) iv or po The rats were killed by CO 2 -asphyxiation after 30 min (one animal given 3 H-2,6-xylidine iv) or 24 h (one animal given 3 H-2,6-xylidine iv and one animal given 3 H-2,6-xylidine orally). They were then embedded in carboxymethyl cellulose and put in a hexane bath cooled to À78 C with CO 2 -ice and used for whole-body sectioning according to the method of Ullberg (Ullberg et al., 1982) . Twenty-mm-thick sagittal sections were taken through the entire bodies. To study the distribution of firmly bound radioactivity, every other freeze-dried tissue-section was extracted successively with 5% trichloroacetic acid, 50% ethanol, 99.5% ethanol, and heptane for 1 min, and then rinsed with tap water for 5 min. These sections, together with the nonextracted tissue-section, were dried and pressed against X-ray film for about 8 weeks (Hyperfilm-3 H, Amersham, Great Britain). To study the distribution of the volatile nonmetabolized 3 H-2,6-xylidine, the surface of each of the sectioned carboxymethyl cellulose-embedded rats was pressed for 7 days at À20 C against phosphor imaging plates (Storage Phosphor Screen, tritium-sensitive, type: TR). Radioluminographic images were then obtained by developing the plates using the Packard Cyclone Storage Phosphor System (Packard, Canberra Company, Japan). nitrenium ion iminoquinone ne rea eactive ester FIG. 1. Proposed activation pathways of 2,6-xylidine. Oxidation of 2,6-xylidine by CYP2A6 or CYP2E1 or by CYP2A6 forms DMAP and DMHA, respectively. DMHA has the potential to react with DNA or hemoglobin. It may also undergo phase II conjugation to reactive esters that can decompose spontaneously to a reactive nitrenium ion, which can react with DNA and other macromolecules. The nitrenium ion can also react with H 2 O to form DMAP. The latter can undergo a non-enzymatic oxidation to an iminoquinone, which is a strong electrophile. DMHA can also be rearranged to DMAP by a CYP2E1-catalyzed reactions (modified after Gan et al., 2001) .
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TYDÉ N ET AL. ethanol [2.4 ml/kg body weight]) and killed by CO 2 -asphyxiation after 24 h. Pieces of the olfactory and respiratory mucosa, trachea, lung, tongue, cheek, soft palate, esophagus, and forestomach were immediately removed and fixed in phosphate buffered 4% formaldehyde (pH 7.4). Following dehydration in an ethanol series the pieces were embedded in Technovit 100 (Heraeus Kulzer GmbN, Wehrheim, Germany). Two-mm-thick sections were cut on glass slides and covered with Kodak NTB-2 emulsion. Exposure was carried out for about 3 months at 4 C, followed by photographic development and fixation and staining of the sections with toluidine blue. The extensive extractions during the fixation and embedding procedures will remove all unbound radioactivity, and the autoradiograms will therefore show only tissue-bound labeling (Larsson, 1994) .
For in vitro microautoradiography one non-pretreated rat was killed by CO 2 -asphyxiation. Pieces of the same tissues as those examined for in vivo microautoradiography (see above) were immediately removed and incubated for 1 h at 37 C in O 2 -atmosphere with 2 mCi 3 H-2,6-xylidine (0.1 mM) in 2 ml Tris-HCl buffer pH 7.4, containing 5 mM glucose-6-phosphate. In some incubations the CYP-inhibitor metyrapone (500 mM) was present in the incubation medium. After the incubations the pieces were fixed in phosphate buffered 4% formaldehyde (pH 7.4) and used for microautoradiography, as described above.
Preparation of subcellular fractions. For preparation of S-9-fractions, pooled samples of various tissues were taken from two pools of 10 non-pretreated rats killed by CO 2 -asphyxiation. The tissues were homogenized in 50 mM phosphate buffer, pH 7.4, and centrifuged at 9000 x g for 20 min. The obtained supernatants (S-9 fractions) were stored at À 70 C until used. For preparation of microsomal fractions, pooled samples of various tissues were taken from two pools of 10 non-pre-treated rats killed by CO 2 -asphyxiation. The tissues were homogenized in 50 mM Tris-HCl buffer, pH 7.4, containing 0.15 M KCl. The homogenates were sedimented at 10,000 x g for 25 min. The resulting supernatants were centrifuged at 105,000 x g for 1 h. The obtained microsomal pellets were washed in the Tris-HCl buffer and re-centrifuged at 105,000 x g for 1 h before re-suspension in the same buffer and storage at À70 C until used.
The protein contents in the microsomal pellets and the S-9-fractions were assayed by the method of Smith et al. (1985) , adapted for microplate readers.
In vitro formation of protein-bound 2,6-xylidine metabolites. To examine the capacity of the tissues to form protein-bound 2,6-xylidine metabolites, incubations were performed with S9-fractions in a total volume of 1 ml of O 2 -saturated 50 mM phosphate buffer containing the same NADPH-generating system as described below. The incubations were carried out at 37 C for 30 min in the buffer containing 0.15 mg protein and 2 mCi 3 H-xylidine (0.2 mM). The incubations were stopped by adding 1 ml ice-cold methanol and 2 ml chloroform. The protein pellet was extracted according to the method of Baker and Van Dyke (1984) , and the amount of protein-bond 3 H-xylidine metabolite was analyzed as described below. Samples of the liver, treated with 1 ml ice-cold methanol and 2 ml chloroform prior to the incubations, served as controls.
In vitro formation of DNA-bound 2,6-xylidine metabolites. To examine the capacity of the tissues to form DNA-bound 2,6-xylidine metabolites in vitro, incubations were performed with microsomal tissue preparations, 3 H-2, 6-xylidine, and calf thymus DNA. Incubations were carried out at 37 C for 30 min in a total volume of 2 ml O 2 -saturated 50 mM Tris-HCL buffer, pH 7.4, containing 0.8 mM NADP, 5 mM glucose-6-phosphate, 1 U glucose-6-phosphate dehydrogenase, 3 mM MgCl 2 , 0.2 mg microsomal protein, 0.5 mg calf-thymus DNA, and 2 mCi 3 H-xylidine (0.1 mM). The reaction was started by adding the 3 H-2,6-xylidine after a 10-min preincubation. The incubations were stopped by the addition of 0.5 ml 4.5 M NaCl and 0.1 ml 3% sodium dodecylsulfate. The amount of 3 H-2,6-xylidine metabolite bound to DNA was determined by extractions and liquid scintillation counting as described elsewhere (Tjälve et al., 1992) , with the exception that the DNA-quantitation was performed with Pico Green Reagent, according to the method of Singer et al. (1997) . Samples of the liver treated with 0.5 ml 4.5 M NaCl and 0.1 ml 3% sodium dodecylsulfate prior to the incubation served as controls.
RESULTS
Whole-Body Radioluminography and Whole-Body Autoradiography
The results of the low-temperature radioluminographywhich will retain volatile radioactive materials in the tissues-of the rat killed 30 min after iv injection of 3 H-2,6-xylidine showed that the level of labeling in adipose tissues at various sites, such as abdominal and subcutaneous regions, was much higher than in other tissues of the body (Fig. 2A) . A high degree of labeling was also present in some nasal glands. Considerable labeling was present in the wall and the adjacent lumen of the glandular part of the stomach. A moderate level of radioactivity was also seen in brain and spinal cord, with a preferential localization in the white matter. The radioluminographic technique makes it possible to detect a wide range of radioactivity levels in various tissues. The radioluminographic image in Figure 2A has been given a threshold that visualizes the most highly labeled structures in the body. Radioluminograms given thresholds that allow visualization of lower levels of radioactivity showed an evenly distribution in most other tissues of the body (data not shown).
In autoradiograms of freeze-dried tissue sections from of the rat killed 30 min after iv injection of 3 H-2,6-xylidine, the volatile labeling had disappeared. In these autoradiograms a high level of labeling was observed in the nasal olfactory mucosa (Fig. 2B) . High levels of radioactivity were also seen in the mucosa in various structures of the upper alimentary tract, such as the tongue, cheek, gingiva, soft palate, esophagus, and forestomach. A somewhat lower degree of labeling was present in the nasal respiratory mucosa and the tracheal, bronchial, and bronchiolar mucosa. In addition, some nasal glands showed a high degree of labeling. In the abdomen, the most highly labeled structures were the kidney (most prominent in the pelvis) and the contents of stomach, small intestine, and urinary bladder. Moderate labeling was present in the blood and-at a somewhat lower level-in the liver. In addition, the autoradiograms showed a considerable degree of labeling in connective tissues at various sites. There was no labeling of adipose tissues or the central nervous system (CNS).
Autoradiography of extracted tissue sections of the rat killed 30 min after iv injection of 3 H-2,6-xylidine showed retention of high levels of bound material in the nasal mucosa and in the mucosa of the upper alimentary tract (Fig. 2C) . A somewhat lower level of labeling was present in the tracheal, bronchial, and bronchiolar mucosa. A low level of bound radioactivity was also present in the blood. In addition, a low degree of labeling was retained in connective tissues, most markedly in the subcutis. The contents of the glandular stomach was also labeled. There was no detectable labeling of other tissues of the body.
Whole-body radioluminograms and whole-body autoradiograms of rats killed 1 day after iv or oral administration of 3 H-2, 6-xylidine showed similar pictures, whether low-temperature radioluminography or autoradiography with freeze-dried tissue C. An autoradiogram of an extracted tissue-section. The radioluminography makes it possible to detect a wide range of radioactivity levels in various tissues. The low-temperature radioluminogram (A) has been given a threshold which visualizes the most highly labeled structures in the body, i.e., primarily adipose tissues at various sites. In the autoradiogram of the freeze-dried tissue section (B) the volatile nonmetabolized sections or extracted tissue sections were used. These pictures showed marked localization of radioactivity in the nasal mucosa and in the mucosa of the tissues of the upper alimentary tract (Fig. 3A) . A somewhat lower level of labeling was present in the tracheal, bronchial, and bronchiolar mucosa. An even lower level of radioactivity was present in the blood and the connective tissues, and there was no detectable labeling in other tissues of the body.
Microautoradiography
The in vivo microautoradiography, which was performed in a rat killed 1 day after iv injection of 3 H-2,6-xylidine, showed labeling over cells of Bowman's glands in the nasal olfactory mucosa, whereas other structures in the olfactory area were unlabeled (Fig. 4A ). In the nasal respiratory mucosa, the acini and ducts of some subepithelial serous glands were labeled, whereas the surface epithelium and subepithelial mucous glands were unlabeled (Fig. 4B ). In the bronchioli (Fig. 4C) , bronchi, and trachea (data not shown) some cells of the surface epithelia were labeled. The lung parenchyma was unlabeled. In the esophagus there was an accumulation of silver grains over the stratum corneum of the surface epithelium (Fig. 4D) , and in the tongue, silver grains were localized over the superficial parts of the stratified squamous epithelium (Fig. 4E) . Comparable pictures were seen in the gingiva, cheek, and soft palate (data not shown). In the forestomach silver grains were limited to a narrow zone in the deepest part of the stratum corneum (Fig. 4F) .
The in vitro microautoradiography of the nasal olfactory mucosa incubated with 3 H-2,6-xylidine showed preferential localization of silver grains over sustentacular cells and a lower degree of labeling of the cells of Bowman's glands (Fig. 5A) . Incubations with nasal respiratory mucosa resulted in labeling of the surface epithelium and of the serous subepithelial glands as well (Fig. 5B) . In the trachea, silver grains were present over some epithelial cells (Fig. 5C ). Comparable pictures were seen in the bronchi and bronchioli (data not shown). In the esophagus, silver grains were localized over the cells of the stratified squamous epithelium, except the   FIG. 3. A. Whole-body autoradiogram of a freeze-dried tissue section of a rat killed 1 day after oral administration of 3 H-xylidine. B. The corresponding tissue-section. Abbreviations: e 5 mucosa of the esophagus; fs 5 mucosa of the forestomach; g 5 mucosa of the gingiva; o 5 nasal olfactory mucosa; sp 5 mucosa of the soft palate; t 5 mucosa of the tongue.
METABOLIC ACTIVATION OF 2,6-XYLIDINE IN RATS
cells of the deepest layers and the stratum corneum (Fig. 5D) . Comparable pictures were seen in the forestomach (data not shown). In the cheek and tongue, silver grains were localized over the cells of the stratified squamous epithelium, except the cells of the deepest layers ( Fig. 5E and 5F ). Comparable pictures were seen in the gingiva and soft palate (data not shown). Microautoradiograms obtained from tissues incubated with 3 H-2.6-xylidrine together with metyrapone were devoid of silver grains.
Formation of Protein-Bound 2,6-Xylidine-Metabolites by Various Tissues
Incubations with S-9-fractions showed that all the examined tissues had a capacity to activate 2,6-xylidine to protein-bound metabolites. The nasal olfactory mucosa showed the highest activating capacity. The activating capacity of the other tissues was in the following order: mucosa of cheek % nasal respiratory mucosa 4 liver % mucosa of tongue 4 mucosa of esophagus % mucosa of forestomach (Table 1) .
Formation of DNA-Bound 2,6-Xylidine-Metabolites by Various Tissues
Incubations with microsomal preparations showed that all the examined tissues had a capacity to form DNA-bound 2, 6-xylidine-metabolites. The nasal olfactory mucosa showed the highest activating capacity. The activating capacity of the other tissues was in the following order: nasal respiratory   FIG. 4 . In vivo microautoradiography of various tissues of a rat killed 1 day after an iv injection of 3 H-xylidine. A. Nasal olfactory mucosa. B. Subepithelial glands of the nasal respiratory mucosa. C. Lung with a bronchiolus. D. Esophagus. E. Tongue. F. Forestomach. In panel A there is a labeling of Bowman's glands; in panel B silver grains are present over the serous gland but not over the mucous gland of the nasal respiratory mucosa; in panel C the silver grains are confined to the bronchiolar epithelium, whereas the lung parenchyma is unlabeled; in panel D the silver grains are localized over stratum corneum of the esophagus; in panel E silver grains are localized over the superficial part of the stratified squamous epithelium of the tongue; and in panel F silver grains are limited to a narrow zone in the deepest part of the stratum corneum of the forestomach. Abbreviations: be 5 bronchiolar epithelium; Bg 5 Bowman's gland; mg 5 mucous gland; n 5 neuronal cells; s 5 sustentacular cells; se 5 stratified squamous epithelium of the esophagus; sf 5 stratified squamous epithelium of the forestomach; sg 5 serous gland; st 5 stratified squamous epithelium of the tongue. Toluidine blue; panels A and D, magnification 3200; C, magnification 3250; B, E, and F, magnification 3300.
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TYDÉ N ET AL. mucosa 4mucosa of esophagus % mucosa of cheek % mucosa of tongue 4 mucosa of forestomach % liver (Table 2) .
DISCUSSION
The results of the low-temperature whole-body radioluminography indicate that the non-metabolized 2,6-xylidine, which is a volatile and fat-soluble compound, is distributed throughout the body and accumulates in adipose tissues, e.g., in the abdominal and subcutaneous regions.
The autoradiography of the extracted whole-body tissuesections, as well as the in vivo microautoradiography, showed bound 2,6-xylidine metabolites in the nasal olfactory mucosa and the mucosa of the upper alimentary and respiratory tracts. These tissues were found to have an in vitro capacity to bioactivate 2,6-xylidine. Thus, our data indicate that 2,6-xylidine in vivo undergoes an in situ bioactivation in these extrahepatic tissues.
It should be noted that the 2,6-xylidine-bioactivation in the extrahepatic tissues is confined to a few cells, such as Bowman's glands in the nasal olfactory mucosa; the acini and ducts of some serous glands in the nasal respiratory mucosa; some cells of the stratified squamous epithelium of the mouth, esophagus, and forestomach; and some cells of the surface epithelium of the trachea, bronchi, and bronchioli. The bioactivating capacity of these cells is reflected by the strong labeling in the autoradiograms and must be higher than is reflected by the in vitro data based on subcellular preparations of these heterogeneous tissues.
FIG. 5.
In vitro microautoradiography of various rat tissues incubated with 3 H-xylidine. A. Nasal olfactory mucosa. B. Nasal respiratory mucosa. C. Trachea. D. Esophagus. E. Cheek. F. Tongue. In panel A there is a preferential labeling of sustentacular cells; in panel B silver grains are present over the nasal respiratory epithelium and over the serous gland; in panel C the silver grains are confined to the tracheal epithelium; in panels D, E, and F silver grains are localized over all cells of the stratified squamous epithelia, except the cells of the deepest layers. Abbreviations: Bg 5 Bowman's gland; n 5 neuronal cells; re 5 nasal respiratory epithelium; s 5 sustentacular cells; se 5 stratified squamous epithelium of the esophagus; sg 5 serous gland; st 5 stratified squamous epithelium of the tongue. Toluidine blue; panel A, magnification 3200; B, C, D, and E, magnification 3300; F, magnification 3150.
METABOLIC ACTIVATION OF 2,6-XYLIDINE IN RATS
As mentioned in the Introduction, Gan et al., (2001) used recombinant human CYPs and human liver microsomes to study the initial CYP-mediated mono-oxygenation of 2,6-xylidine. They identified CYP2A6 and CYP2E1 as the major CYPs responsible for the formation of DMAP, i.e., hydroxylation of 2,6-xylidine in the para position on the aromatic ring, and CYP2A6 as being responsible for the formation of DMHA, i.e., hydroxylation of the nitrogen of 2,6-xylidine. In addition DMHA can be rearranged to DMAP by a CYP2E1-catalyzed reaction (Gan et al., 2001 ; see Fig. 1 ).
It is well known that high levels of some CYP-enzymes are present in the nasal olfactory mucosa and the mucosa of the upper alimentary and respiratory tracts (Ding and Kaminsky, 2003; Thornton-Manning and Dahl, 1997) . CYP2A3, which is the rat ortholog of human 2A6, is expressed at high concentrations in the rat nasal mucosa (Thornton-Manning and Dahl, 1997) . CYP2A3 has been shown in the esophagus of rats (Gopalakrishnan et al., 1999; Pinto et al., 2001) . CYP2E1 has been shown in the rat nasal mucosa (Thornton-Manning and Dahl 1997). Shimizu et al. (1990) showed ethanol-inducible CYP2E1 in the squamous epithelial cells of the esophagus, cheek, tongue, and forestomach in rats. The mucosa cells of the tracheobronchial airways of rats also express CYP2E1 (Watt et al., 1998 ). It appears that relevant CYP-enzymes are present at the sites of 2,6-xylidine bioactivation. The microautoradiographic observation that the covalent in vitro binding of 2,6-xylidine-metabolites in these structures was completely blocked by the CYP inhibitor metyrapone confirms that the bioactivation is CYP dependent. However, further studies are required to determine the detailed role of the individual CYPs in the bioactivation of 2,6-xylidine in these tissues. It is also possible that CYPs other than 2A3/2A6 and 2E1 may be involved in the bioactivation of 2,6-xylidine at these sites.
Our results showed that the nasal olfactory mucosa had a much higher capacity than the other examined tissues to bioactivate 2,6-xylidine. The structures in the olfactory mucosa engaged in the bioactivation of 2,6-xylidine have been shown to contain high levels of CYP enzymes (Brittebo, 1997; Thornton-Manning and Dahl, 1997) . Thus, the carcinogenic effect of 2,6-xylidine on the nasal mucosa is correlated with a high capacity of this tissue to bioactivate the compound. The in vivo microautoradiographs of the nasal mucosa indicate that the bioactivation of 2,6-xylidine is very active in Bowman's glands in the lamina propria, and that a considerable bioactivation also occurs in some serous submucosal glands. The in vivo microautoradiography indicated lack of bioactivation of 2,6-xylidine in the sustentacular cells, whereas the in vitro microautoradiography indicated a bioactivation in these cells. It is possible that under in vivo conditions the high metabolic capacity of Bowman's glands, which are situated close to the capillaries in the lamina propria, may prevent 2,6-xylidine from reaching the sustentacular cells.
As mentioned in the Introduction, administration 3000 ppm of 2,6-xylidine in the diet to rats for 4 weeks has been reported to result in atrophy of Bowman's glands in the dorsal meatus of the olfactory region of the nasal cavity (Yasuhara et al., 2000) . The present data indicate that this effect can be related to the formation of cytotoxic 2,6-xylidine-metabolites in Bowman's glands. Conceivably Bowman's glands may also be the structures in the olfactory mucosa that undergo the malignant transformations. It has been shown that the herbicide 2,6-dichlorobenzonitrile (dichlobenil) administered parenterally to mice causes necrosis of the nasal olfactory mucosa after an initial bioactivationrelated injury of Bowman's glands (Brandt et al., 1990) . It has been shown that CYPs of the isoforms 2A6 and 2E1-i.e., those assumed to bioactivate 2,6-xylidine-are active in the metabolism of dichlobenil in the nasal mucosa (Ding et al., 1996) .
There are no reports that the squamous epithelia of the esophagus, the mouth, and the forestomach, which were found to have a capacity to form DNA-binding 2,6-xylidinemetabolites, will undergo malignant transformations in rats treated with this compound. Neither are there any reports of 2,6-xylidine-induced tumors in the tracheo-bronchial mucosa. The reason for this is not known, but one possibility is that the potent bioactivation of 2,6-xylidine in the nasal mucosa leads to tumor development at this site before malignancies will develop at the other sites. With regard to the squamous epithelium of the upper alimentary tract, there is also a possibility that, because of the cellular turnover in the stratum corneum, the cells will be expelled before any malignant transformation occurs. Our results showed that the in vivo labeling of the stratified squamous epithelium of the esophagus, gingiva, tongue, soft palate, and forestomach-in contrast to the in vitro situation-was confined to the superficial layers of the epithelium. It is possible that under the in vivo conditions the cells in the squamous epithelium will bioactivate the 2,6-xylidine during a relatively short period when nonmetabolized substance is available for metabolism. At the 1-day survival interval, which was used for the microautoradiography, the labeled 2,6-xylidine-bioactivating cells may have been transferred toward the surface of the epithelium and replaced by basally located nonlabeled cells.
In humans, in contrast to rodents, the nasal mucosa is a very unusual site of tumorigenesis. Thus, chemical carcinogens, such as 2,6-xylidine, which in humans may be bioactivated in the nasal olfactory mucosa, as well as the mucosa of the upper alimentary and respiratory tissues, might potentially be expected to be more prone to induce tumors at the latter sites than in the nasal olfactory mucosa. Of special concern in this respect is the squamous epithelium of the upper alimentary tract, in which CYP2E1 may be induced by chronic ethanol intake, leading to xenobiotic activation and potentially ethanol-related tumorigenesis.
The 2-year carcinogenicity study of 2,6-xylidine showed a slightly increased incidence of subcutaneous fibromas in treated rats (Kornreich and Montgomery, 1990) . It can be assumed that these tumors develop from fibroblasts in the subcutaneous connective tissue. Our whole-body autoradiography of the dried and extracted tissue sections showed uptake of labeled material in the subcutaneous connective tissues of the 3 H-2,6-xylidine-treated rats. To our knowledge there are no reports that fibroblasts in connective tissues contain CYP-enzymes, which potentially might bioactivate 2,6-xylidine. Alternatively, a non-enzymatic bioactivation might occur in the fibroblasts. Thus, it is possible that hydrophilic DMHA-esters, formed in tissues with bioactivating capacity, will be translocated to the connective tissues, which may be reached via the fenestrated capillaries at these sites, and that they then may decompose non-enzymatically to an electrophilic nitrenium ion, as shown in Figure 1 .
The low-temperature whole-body radioluminography of the rat killed 30 min after 3 H-2,6-xylidine administration showed a considerable degree of labeling in the wall and the adjacent lumen of the glandular stomach. We assume that this represents protonated 2,6-xylidine. In the acidic milieu of the glandular stomach, the substance may undergo protonization at the nitrogen atom and therefore accumulate at this site as a result of ion-trapping. The whole-body autoradiography of extracted sections of this rat showed high levels of radioactivity bound to the contents of the glandular stomach. In contrast, the radioactivity in the other parts of the alimentary tract was extractable. The mechanism underlying the retention of bound labeling in the contents of the stomach is not known. However, one possibility is that nitrite ions reaching the stomach lumen via the saliva or feed react with the protonated 2,6-xylidine, which in the acidic milieu may form a positively charged electrophilic diazonium ion that reacts with feed components.
The whole-body autoradiographs showed bound labeling in the blood. We assume that this represents 2,6-xylidine hemoglobin adducts.
The nasal olfactory mucosa and the mucosa of the upper respiratory and alimentary tracts have previously been shown to have the capacity to perform CYP-related bioactivation of other compounds, such as the haloalkanes chloroform, carbon tetrachloride, and halothane (Tjälve and Löfberg, 1983; Löfberg and Tjälve, 1986; Ghantous et al., 1988) , several N-nitrosamines (Tjälve 1991) , the mycotoxin aflatoxin B 1 (Larsson 1994) , the sweet potato furanoterpenoid ipomeanol (Larsson and Tjälve, 1988) , the herbicides dichlobenil and chlorthiamide (Brandt et al., 1990; Brittebo et al., 1991) , and the 2,6-dichlorobenzenemetabolite methylsulfonyl-2,6-dichlorobenzene (Bahrami et al., 1999; Franzén et al. 2003) . The CYP enzymes active in these tissues, which are portals of entry for foreign compounds, may normally play a role in defending the body from unrestrained uptake of xenobiotics. However, for chemicals that are bioactivated by CYP-dependent reactions, cellular injuries, or transformations leading to malignancies may instead be induced.
